Linear Clinical Research Current Trials Menu

Compare Trials

Healthy Volunteer Studies

LE180508 | Autoimmune Disease Study

Visit Schedule

6 nights and 7 days with 1 follow-up appointment

You Get $1900!

STUDY TIMELINES Cohort 1.2
Confinement Check-In 21-Oct-18
Check-Out 27-Oct-18
Follow-Up Day 10 31-Oct-18

 

Testing a medication for the treatment of autoimmune diseases such as Multiple Sclerosis.

Inclusion Criteria

  • Healthy Males and Females between the ages of 18 and 55
  • BMI must be between 18 – 30.5 kg/m2
  • Must be free from any clinically significant illness or disease
  • Females must be of non-childbearing potential (either surgically sterile or postmenopausal)
  • Must be non-smokers (for at least the last 6 months)

APPLY NOW

 

LE180501 | Cardiovascular Disease Study

Help us test a new treatment for Cardiovascular Disease (CVD) and elevated plasma Lipoprotein(a) levels. Cardiovascular disease kills one Australian every 12 minutes (The Heart Foundation). Participating in this trial means you’ll be supporting world leading research into improving treatments.

You Get $2550! 

(remuneration based on completion of in-house stay and all follow-up appointments)

This Research is being run by a world leading expert in this area, Professor Gerald Watts.

 Potential Visit Schedule

5 day stay with 11 appointments spread across 5 months 

LE180501 Example Study Timeline COHORT 4

In-House Check-In 11-Nov
Check-Out 15-Nov
Follow up Day 7 18-Nov
Day 15 26-Nov
Day 18 29-Nov
Day 22 03-Dec
Day 29 10-Dec
Day 43 24-Dec
Day 57 07-Jan
Day 71 21-Jan
Day 85 04-Feb
Day 113 04-Mar
End of Study Day 155 15-Apr

 

Inclusion Criteria

  • Healthy Males and Females, aged between 18 and 60
  • Females must be of Non-Childbearing Potential (either Surgically Sterile or Postmenopausal)
  • Body Mass Index (BMI) between 18 – 32 kg/m2
  • Elevated plasma Lipoprotein(a) level ≥70 and ≤199nmol/L, confirmed by a pre-screen blood test
  • Not currently on any medications with the exception of Statin, lipid-lowering medications (for certain cohorts only)
  • Participants must be non-smokers (Have not used any nicotine containing products in the last 6 months)

APPLY NOW

 

 

LE180701 | NAFLD Study

Help us test a new treatment for non-alcoholic fatty liver disease (NAFLD)! The cause of this disease is unknown and most people have no symptoms.

You Get $2050! 

(remuneration based on completion of in-house stay and all follow-up appointments)

One 2 night, 3 day stay & 10 appointments

LE180701 TIMELINES
Groups Group 1 Group 2
Confinement Check-In 21-Oct-18 25-Oct-18
Check-Out 23-Oct-18 27-Oct-18
Follow up Day 3 24-Oct-18 28-Oct-18
Day 5 26-Oct-18 30-Oct-18
Day 8 29-Oct-18 02-Nov-18
Day 15 05-Nov-18 05-Nov-18
Day 22 12-Nov-18 09-Nov-18
Day 30 20-Nov-18 16-Nov-18
Day 45 05-Dec-18 24-Nov-18
Long-term Follow up Day 60 20-Dec-18 24-Dec-18
Day 75 05-Jan-19 09-Jan-19
End of Study Day 90 19-Jan-19 23-Jan-19

 

Inclusion Criteria

  • Healthy Males and Females, aged between 18 and 45
  • Body Mass Index (BMI) between 25 – 40 kg/m2
  • Participants must not have any severe allergies
  • Must be free from any clinically significant illness or disease
  • Participants must be non-smokers 

APPLY NOW

LE180507 | HAE Study Part B

Visit Schedule

16 nights and 17 days with 1 follow-up appointment

You Get $4350!

 

Cohort Confinement Period 

Follow-up Appointment

Check-in Check-out Day 21
4 30 Oct 18 15 Nov 18 20 Nov 18

 

Testing a medication for the treatment of a condition involving swelling (HAE).

Inclusion Criteria

  • Healthy Males between the ages of 18 and 55
  • BMI must be between 18 – 30 kg/m2
  • Must be free from any clinically significant illness or disease
  • Must be non-smokers (for at least the last 2 months)
  • Participants must be willing to refrain from strenuous exercise from 7 days prior to check-in until completion of the study.

APPLY NOW

LE17122 | HAE Study Part A

Help us test a medication for the treatment of Hereditary Angioedema (HAE), a life threatening disease associated with swelling and airway obstruction.

You Get $1630!

(This payment is remuneration based on completing all dates for this cohort)

Visit Schedule: Possibility of change

3 nights and 4 days with 1 follow-up appointment

 

Cohort In-house stay

Appointment

Check-in

Day -1

Check-out

Day 3

Day 8
6 A 05 Nov 08 Nov 13 Nov
6 B 06 Nov
09 Nov
14 Nov

 

Inclusion Criteria

  • Healthy Males between the ages of 18 and 55
  • BMI must be between 18 – 30 kg/m2
  • Must be free from any clinically significant illness or disease
  • Must be non-smokers (for at least the last 2 months)
  • Participants must be willing to refrain from strenuous exercise from 7 days prior to check-in until completion of the study.
  • Must have a heart rate be between 50 – 90 bpm

APPLY NOW

 

 

LE180709 | Angiodema Study Part A

Visit Schedule

3 nights and 4 days with 1 follow-up appointment

You Get $1330!

LE180709 STUDY TIMELINES Cohort 2
Confinement Check-In 29-Oct-18
Check-Out 01-Nov-18
Follow-Up Day 8 06-Nov-18

 

Testing a medication for the treatment of a condition involving life-threatening swelling, Hereditary Angioedema (HAE).

Inclusion Criteria

  • Healthy Males between the ages of 18 and 55
  • BMI must be between 18 – 30 kg/m2
  • Must be free from any clinically significant illness or disease
  • Must be non-smokers (for at least the last 2 months)
  • Participants must be willing to refrain from strenuous exercise from 7 days prior to check-in until completion of the study.
  • Please Note: This study requires that you have a heart rate between 50 and 90bpm.

APPLY NOW

 

LE180709 | Angioedema Study Part B

Visit Schedule

16 nights and 17 days with 1 follow-up appointment

You Get $4350!

 

Cohort Confinement Perio

Follow-up Appointment

Check-in Check-out Day 21
1 12 Nov 18 28 Nov 18 03 Dec 18

 

Testing a medication for the treatment of a condition involving swelling (HAE).

Inclusion Criteria

  • Healthy Males between the ages of 18 and 55
  • BMI must be between 18 – 30 kg/m2
  • Must be free from any clinically significant illness or disease
  • Must be non-smokers (for at least the last 2 months)
  • Participants must be willing to refrain from strenuous exercise from 7 days prior to check-in until completion of the study.

APPLY NOW

LE17124 | Hearing Loss Study

 

ON HOLD

Investigating a new treatment for children with cancer who suffer hearing loss as a result of exposure to chemotherapy drugs. It is estimated that, on average, about 750 children aged 0-14 years old are diagnosed with cancer each year in Australia (Cancer Council). Participating in this trial means you’ll be supporting world leading research into improving hearing loss treatments for these children.

You Get $2320! 

(This payment is based on completing the in-house stay and all scheduled appointments)

Visit Schedule

2 nights and 3 days with one follow up phone call and three in-house follow-up appointments

 

LE17124

STUDY TIMELINES

Cohort 1.1 Cohort 1.2 Cohort 1.3 Cohort 1.4 Cohort 1.5
Confinement Check-In 21-Oct 28-Oct 04-Nov 07-Nov 11-Nov
Check-Out 23-Oct 30-Oct 06-Nov 09-Nov 13-Nov
Follow Up Day 4 (phone call) 25-Oct 01-Nov 08-Nov 11-Nov 15-Nov
Day 8 29-Oct 05-Nov 12-Nov 15-Nov 19-Nov
Day 15 05-Nov 12-Nov 19-Nov 22-Nov 26-Nov
Day 30 20-Nov 27-Nov 04-Dec 07-Dec 11-Dec

 

Inclusion Criteria

  • Healthy Males and Females, aged between 18 and 65
  • Body Mass Index (BMI) between 18 – 35 kg/m2
  • Normal hearing,  defined as ≤20 dB from 250 Hz to 8 kHz bilateral
  • No allergies to any local anesthetics (numbing medication)
  • Free from any clinically significant illness or disease as determined by their medical history.
  • Must be willing to attend a hearing test if eligible after first screening visit.

LL17035 | Malaria Study

Visit Schedule
*Appointments Only*

Participants will be required to attend 7 – 10 appointments. 

Part 1
Treatment (Week 1-52)
Part 2
Follow-up
Part 3 (Only if required)
Visit 2 3 4 5 6 7a 7b 8 9 10
Week 1 4 12 24 52 64 64 76 89 104
Hours 2-3 2 3-4 3-4 3-4 3-4 3-4 1-2 1-2 1-2
Payment $490 $700 $810 $880 $210 $210 $210

 

Participants who complete the study up to Week 64 will receive in total $2,880

Inclusion Criteria

  • Healthy males and females between the ages of 18 and 55
  • Must agree to stay in contact with the study site for the duration of the study and up to Week 64 (Visit 7b). Have no current plans to move away from Perth for the duration of the study
  • Must maintain a diary throughout the study
  • No eye conditions or use of prescription eye drops

APPLY NOW

 

 

 

Patient Studies

LL17041 | C Diff Vaccine Study

Visit Schedule

Participants will receive 3 vaccination injections over a period of 6 months. There will be a total of 5 outpatient visits to attend, and 2 follow up phone calls across a period of 12 months.

Participants will receive $67 for each visit attended.

Inclusion Criteria

  • Males and females older than 60 years
  • BMI must be between 18-40 kg/m2
  • Must have an increased chance of future contact with healthcare systems by virtue of:
    • At least one inpatient hospitalisation of at least 2 nights in the last 12 months; or
    • At least 2 emergency room visits in the last 12 months; or
    • At least 10 outpatient visits (primary and/or secondary care visits) in the last 12 months; or
    • Taken antibiotics in the last 12 weeks; or
    • Residence in a nursing home

     

    APPLY NOW